Keytruda, Merck and Colorectal Cancer
MRK's Keytruda Combo Fails in Phase III Colorectal Cancer Study
Merck MRK announced data from the phase III KEYFORM-007 study, which evaluated a fixed-dose combination of its anti-LAG-3 antibody, favezelimab and its blockbuster anti-PD-1 therapy, Keytruda in pre-treated patients with PD-L1 positive microsatellite stable (MSS) metastatic colorectal cancer (mCRC).
Merck's Keytruda-LAG-3 combo fails to tame tough colorectal cancer in phase 3
An attempt by Merck & Co. to unlock the microsatellite stable (MSS) metastatic colorectal cancer market has ended in failure. | An attempt by Merck & Co. to unlock the microsatellite stable metastatic colorectal cancer market has ended in failure.
Merck's Experimental Favezelimab/Keytruda Combo Fails In Late-Stage Colorectal Cancer Study
Merck & Co Inc (NYSE:MRK) released topline data from the KEYFORM-007 Phase 3 study of the fixed-dose combination of favezelimab and pembrolizumab versus the standard of care for pretreated patients with microsatellite-stable (MSS) metastatic colorectal cancer (mCRC).
Merck: Favezelimab/Keytruda Combo Study Misses Goal in Colorectal Cancer
Merck is studying Keytruda, a cancer drug that harnesses a patient's immune system to fight tumors, in a raft of trials across a wide variety of cancers and treatment settings. The company is evaluating the Keytruda/favezelimab combination across multiple solid tumor types and in patients with relapsed or refractory classical Hodgkin lymphoma.
Merck’s Keytruda Combo Fails in Phase III Colorectal Cancer Study
Merck follows in the footsteps of Bristol Myers Squibb, which in December 2023 also failed to secure a late-stage victory for its combo regimen of a PD-1 blocker and an anti-LAG-3 antibody.
Merck's colorectal cancer therapy fails late-stage trial
Merck said on Wednesday a combination of its experimental drug and blockbuster therapy Keytruda failed a late-stage trial testing it in previously treated patients with a type of colorectal cancer. Th
GlobalData on MSN1d
MHLW approves MSD’s KEYTRUDA for lung and urothelial cancers
A humanised monoclonal antibody, KEYTRUDA can enhance the immune system's potential to detect and combat tumour cells.
STAT2d
The science behind Summit’s success, 23andMe’s fate, and more biotech news updates
Amgen's immunology drug results —The Novo Nordisk Senate hearing —Sanofi's soul-searching Read on to learn more.
BioSpace9d
Despite Win Over Keytruda, Summit’s NSCLC Bispecific Still Has Something to Prove
Summit Therapeutics’ ivonescimab has the potential to challenge Merck’s blockbuster checkpoint inhibitor in non-small cell ...
FiercePharma12d
ESMO: With survival win, Merck's Keytruda redeems itself in early triple-negative breast cancer
In 2021, the FDA blasted Merck for using a premature endpoint to pursue a Keytruda approval in early-stage triple-negative ...
Merck's Keytruda Secures First FDA-Approval For Rare Form Aggressive Cancer
Keytruda (pembrolizumab) in combination with pemetrexed and platinum chemotherapy for the first-line treatment of adult ...
FierceBiotech13d
ESMO: IO Biotech's vaccine and Keytruda combo hits primary endpoint in phase 2 squamous cell carcinoma trial
Immune checkpoint inhibitors are the superheroes of cancer therapy. | Immune checkpoint inhibitors are the superheroes of ...
Cure Today13d
Keytruda Plus Chemoradiotherapy May Represent New Standard of Care in Cervical Cancer Subset
Patients with previously untreated, high-risk locally advanced cervical cancer experienced improved survival when treated ...
STAT2d
The little-known Chinese biotech whose cancer drug beat Keytruda has global ambitions
Recent headlines about a potent new immunotherapy have mostly focused on the U.S. company helping to develop it. Less ...